0
0
Home » Pharmaceuticals

Eosinophilic Esophagitis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Stratergies and Forecast, 2020 – 2030

The eosinophilic esophagitis (EoE) market in the US was valued at $156.7 million in 2020. The market is projected to grow at a CAGR of more than 25% during the forecast period. The COVID-19 pandemic did not impact the EoE market in 2020. Although the uptake of high-priced biologics is expected to be slow, they are expected to capture significant growth revenue over the next 10 years.

A large number of symptomatic treatments are currently used off-label. The most frequently used drug classes are proton pump inhibitors and corticosteroids. The most commonly used off-label proton pump inhibitors for EoE are omeprazole and pantoprazole. The most commonly corticosteroids used off-label for EoE are budesonide and fluticasone propionate. The greatest unmet needs within the EoE market are lack of data, more effective or curative therapies, increased awareness and education, and more options for the pediatric population.

Overview of the eosinophilic esophagitis market

Overview of the eosinophilic esophagitis market

For more insights, download a free sample

What are the market dynamics in the eosinophilic esophagitis market?

EoE is still a relatively poorly understood entity. Increasing emphasis has been placed on the role of food allergy but development of eosinophilic esophagitis may be multifactorial, with contributing factors including inflammatory mediators, genetic susceptibility, environmental factors, atopic conditions, dietary products, esophageal microbiome, and oral immunotherapy.

The pathogenesis of EoE is unknown. However, it likely results from an interplay of genetics, the immune system, environmental factors, and mechanisms of mucosal damage and fibrosis. EoE is associated with T helper cell-2 (Th2) type immune responses, similar to other atopic conditions. The endoscopic assessment of the esophagus has shown elevated levels of the Th2 cytokines interleukin (IL)-4, IL-5, and IL-13, as well as mast cells, in the esophageal mucosal biopsies of EoE patients

The sales of high-priced biologics represent the most impactful driver of growth for the EoE market. The launch of Dupixent (dupilumab) for pediatrics, adolescents, and adults is expected to increase the sales significantly. Also, low diagnosis rates caused by limited disease awareness will continue to keep the diagnosed cases at a low rate.

What are the key drugs used in the eosinophilic esophagitis market?

Off- label PPIs (omeprazole, pantoprazole), Off- label GRAs (budesonide and fluticasone propionate), Eohila (budesonide), APT- 1011 (fluticasone propionate), Cendakimab (RPC- 4046), Fasenra (benralizumab), and Dupixent (dupilumab) are the key drugs used in the eosinophilic esophagitis market.

By 2030, the EoE market is expected to have a flood of marketed drugs. Reformulations of budesonide and fluticasone propionate are expected to receive FDA approval and launch as Eohilia and APT-1011, respectively. Additionally, innovative entrants such as cendakimab (RPC-4046), Fasenra (benralizumab), and Dupixent (dupilumab) are expected to gain positions in the EoE market.

Eosinophilic esophagitis market, by drug type

Eosinophilic esophagitis market, by drug type

For more drug type insights, download a free sample

What is the overview of eosinophilic esophagitis market?

The EoE pipeline consists of 11 drugs across all stages of development, with five drugs expected to launch in the forecast period (APT-1011, Eohilia, Dupixent, Fasenra, and cendakimab).

Eight out of 10 pipeline agents are first-in-class drugs with novel mechanisms of action to the EoE market, including interleukin inhibitors (IL-13, IL-4, and IL-5 receptor subunit alpha inhibitors), a mast cell stabilizer, a sphingosine 1-phosphate receptor agonist, an anti-inflammatory, an allergen desensitization immunotherapy, and a lanthionine synthetase component c-like protein 2agonist.

Which are the key companies in the eosinophilic esophagitis market?

Takeda Pharmaceuticals, Ellodi Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals (Sanofi), Allakos Inc, Arena Pharmaceuticals, Revolo Biotherapeutics, DBV Technologies, and Landos Biopharma are the key companies in the eosinophilic esophagitis market.

Eosinophilic esophagitis market, by key companies

Eosinophilic esophagitis market, by key companies

For more key company insights, download a free sample

Market report scope

Market size in the US (2020) $156.7 million
Forecast period 2020-2030
CAGR >25%
Key drugs Off- label PPIs (omeprazole, pantoprazole), Off- label GRAs (budesonide and fluticasone propionate), Eohila (budesonide), APT- 1011 (fluticasone propionate), Cendakimab (RPC- 4046), Fasenra (benralizumab), and Dupixent (dupilumab)
Key companies Takeda Pharmaceuticals, Ellodi Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals (Sanofi), Allakos Inc, Arena Pharmaceuticals, Revolo Biotherapeutics, DBV Technologies, and Landos Biopharma

This report provides an overview of eosinophilic esophagitis. The report includes:

  • Overview of EoE including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline EoE market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting EoE therapeutics sales in the US.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the US EoE therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the US EoE therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US EoE market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Track drug sales in the US EoE therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

Takeda Pharmaceuticals

Ellodi Pharmaceuticals

Bristol Myers Squibb

AstraZeneca

GlaxoSmithKline

Regeneron Pharmaceuticals (Sanofi)

Allakos Inc

Arena Pharmaceuticals

Revolo Biotherapeutics

DBV Technologies

Landos Biopharma

Table of Contents

1 Table of Contents (PowerPoint Deck)

1 Executive Summary

1.1 Executive Summary

2 Disease Overview

2.1 Overview of Eosinophilic Esophagitis

2.2 Eosinophilic Esophagitis SWOT Analysis

3 Epidemiology

3.1 Lifetime Diagnosed Prevalent Cases of EoE, All Ages, Both Sexes, 2020–2030

3.2 Sources and Methodology for Lifetime Diagnosed Prevalent Cases of EoE

4 Current Treatment Options

4.1 Treatment Paradigm

4.2 Treatment Algorithm

4.3 Marketed Products

4.4 Product Profile: Proton Pump Inhibitors

4.5 Product Profile: Glucocorticoid Receptor Agonists

5 Unmet Needs and Opportunities

5.1 Lack of Data

5.2 More Effective or Curative Therapies

5.3 Increased Awareness and Education

5.4 Treatment Options for the Pediatric Population

6 Pipeline Assessment

6.1 Eosinophilic Esophagitis Pipeline Overview

6.2 Leading Pipeline Agents

6.3 Product Profile: Takeda Pharmaceutical’s Eohilia (budesonide)

6.4 Product Profile: Ellodi Pharmaceuticals’ APT-1011 (fluticasone propionate)

6.5 Product Profile: Bristol Myers Squibb’s Cendakimab (RPC-4046)

6.6 Product Profile: AstraZeneca’s Fasenra (benralizumab)

6.7 Product Profile: Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab)

6.8 Product Profile: Allakos’ Lirentelimab (AK-002)

7 R&D Strategies

7.1 Trends in Clinical Trial Design in Eosinophilic Esophagitis

7.2 FDA Treatment Guidance for Industry – EoE

7.3 Trends in Deal-Making in Eosinophilic Esophagitis

8 Market Outlook

8.1 Eosinophilic Esophagitis Market Forecast

8.2 Impact of COVID-19 on Eosinophilic Esophagitis

8.3 Market Drivers and Barriers

9 Appendix

9.1 Bibliography

9.2 Primary Research: KOL Information

9.3 About the Authors

10 Contact Us

Frequently Asked Questions

The eosinophilic esophagitis market in the US was valued at $156.7 million in 2020.

Off- label PPIs (omeprazole, pantoprazole), Off- label GRAs (budesonide and fluticasone propionate), Eohila (budesonide), APT- 1011 (fluticasone propionate), Cendakimab (RPC- 4046), Fasenra (benralizumab), and Dupixent (dupilumab) are the key drug types used in the eosinophilic esophagitis market.

Takeda Pharmaceuticals, Ellodi Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals (Sanofi), Allakos Inc, Arena Pharmaceuticals, Revolo Biotherapeutics, DBV Technologies, and Landos Biopharma are some of the key companies in the eosinophilic esophagitis market.

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports